Imipramine-Induced Inappropriate ADH Secretion

B, Liskin; Bt, Walsh; Sp, Roose; Jackson, Wynn

doi:10.1097/00004714-198406000-00007

Cited by 31 publications

(14 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Weight gain and rare cases of the syndrome of inappropriate antidiuretic hormone secretion and galactorrhoea have also been reported, as have rare cases of haematological or hepatic disease (Grace et at. 1970;Hnatho et al 1965;Klein et al 1964;Liskin et al 1984;Shaefer et al 1990). …”

Section: Adverse Effects Profilementioning

confidence: 99%

Risks and Benefits of Drugs Used in the Management of the Hyperactive Child

Fox

Rieder

1993

Drug Safety

View full text Add to dashboard Cite

Childhood hyperactivity is a common behavioural complaint. The therapeutic options for physicians caring for children with hyperactivity are considerable and varied; current recommendations call for a multidisciplinary approach, including when necessary the use of drug therapy. Central nervous system stimulants are the primary agents used in the therapy of hyperactivity. The majority of children with hyperactivity diagnosed using careful clinical criteria will demonstrate short term benefits in cognitive and behavioural terms, but long term efficacy remains controversial. There appears to be a subset of patients who do not demonstrate a beneficial response to stimulants, although there is controversy as to whether this may be dose dependent. The adverse effects of most concern are suppression of growth, the development of tics and the potential for abuse. Antidepressants and clonidine are useful agents for the therapy of patients resistant to stimulant therapy. Although the most frequent adverse events of antidepressant therapy are associated with the anticholinergic activity of these agents, the most common serious adverse events are associated with antidepressant overdose. Concern has been expressed because of case reports describing an association between antidepressant therapy for hyperactivity and sudden death. A number of other therapies have been used for hyperactivity. Although these therapies may be effective in subsets of patients with hyperactivity, there is little research detailing how to identify patients who might be expected to respond to such treatment.

show abstract

Section: Adverse Effects Profilementioning

confidence: 99%

Risks and Benefits of Drugs Used in the Management of the Hyperactive Child

Fox

Rieder

1993

Drug Safety

View full text Add to dashboard Cite

show abstract

“…10 Onset of hyponatraemia in these cases ranged from 1 week to 1 month after commencement of bupropion. [9][10][11][12] The potential mechanism for how bupropion may cause hyponatraemia has not previously been discussed. Bupropion acts by selective inhibition of the neuronal reuptake of catecholamines (noradrenaline and dopamine) and has minimal effect on reuptake of serotonin.…”

Section: Discussionmentioning

confidence: 99%

Hyponatraemia and confusion in a 70-year-old female when bupropion was added to dothiepin and escitalopram

Wiggins

Balasubramanian

Ferraro

2015

Australas Psychiatry

View full text Add to dashboard Cite

Our case and review of the available literature highlights the dangers of polypharmacy in the management of treatment-resistant depression. Our findings suggest that the association of hyponatraemia with bupropion in our and subsequent cases was likely the result of medication interaction and not a direct side effect of bupropion. Where bupropion is being used as an augmenting agent in the treatment of depression we would suggest checking of serum sodium prior to commencement of bupropion, and monitoring thereafter. This is especially important in elderly patients where other risk factors for hyponatraemia are likely to be present.

show abstract

“…Hyponatremia can occur with SSRIs, SNRIs, and mirtazapine. Although at least two published case reports attribute hyponatremia to bupropion, other factors that may have been responsible for the hyponatremia also were present [61,62].…”

Section: Hyponatremiamentioning

confidence: 99%

Medically serious adverse effects of newer antidepressants

Mago

Mahajan²,

Thase³

2008

Curr Psychiatry Rep

View full text Add to dashboard Cite

Although safer than tricyclic antidepressants and monoamine oxidase inhibitors, the newer antidepressants may be associated with certain medically serious adverse effects, of which cardiovascular adverse effects, seizures, abnormal bleeding, hyponatremia, and agranulocytosis are discussed in this review. Data regarding the incidence and risk factors are summarized, and strategies for reducing the risk of these adverse effects and managing them are suggested. Identification of risk factors, appropriate antidepressant choice, and, when possible, careful monitoring may substantially reduce the incidence of these adverse effects and the morbidity associated with them.

show abstract

Imipramine-Induced Inappropriate ADH Secretion

Cited by 31 publications

References 0 publications

Risks and Benefits of Drugs Used in the Management of the Hyperactive Child

Risks and Benefits of Drugs Used in the Management of the Hyperactive Child

Hyponatraemia and confusion in a 70-year-old female when bupropion was added to dothiepin and escitalopram

Medically serious adverse effects of newer antidepressants

Contact Info

Product

Resources

About